Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $762.3 million.

  • Abivax's Liabilities and Shareholders Equity changed N/A to $762.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 9636.77%. This contributed to the annual value of $219.3 million for FY2024, which is 3801.22% down from last year.
  • As of Q3 2025, Abivax's Liabilities and Shareholders Equity stood at $762.3 million.
  • In the past 5 years, Abivax's Liabilities and Shareholders Equity ranged from a high of $762.3 million in Q3 2025 and a low of $77.1 million during Q4 2022
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $197.5 million (2024), whereas its average is $269.1 million.
  • Per our database at Business Quant, Abivax's Liabilities and Shareholders Equity skyrocketed by 35657.56% in 2023 and then crashed by 5579.51% in 2025.
  • Abivax's Liabilities and Shareholders Equity (Quarter) stood at $125.0 million in 2021, then crashed by 38.32% to $77.1 million in 2022, then skyrocketed by 356.58% to $351.9 million in 2023, then tumbled by 37.68% to $219.3 million in 2024, then soared by 247.59% to $762.3 million in 2025.
  • Its last three reported values are $762.3 million in Q3 2025, $135.4 million for Q2 2025, and $175.6 million during Q1 2025.